<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395237</url>
  </required_header>
  <id_info>
    <org_study_id>BEQ14393</org_study_id>
    <nct_id>NCT02395237</nct_id>
  </id_info>
  <brief_title>COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.</brief_title>
  <official_title>An Open-label, Randomized, Two-treatment Crossover Bioequivalence Study Comparing Two Batches of the Same Fixed Dose Combinations Amaryl® M IR 2/1000 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmaceutical Research Unit, Jordan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi-aventis Liban SAL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmaceutical Research Unit, Jordan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess, after single oral administration under fed&#xD;
      conditions, the bioequivalence between the two batches of the same glimepiride/metformin&#xD;
      hydrochloride (HCl) 2 mg/1000 mg fixed dose combination (FDC) tablets (immediate release&#xD;
      combination tablet Amaryl® M IR 2/1000) manufactured in India and in Turkey.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, two-treatment crossover bioequivalence study comparing two batches&#xD;
      of the same fixed dose combinations Amaryl® M IR 2/1000 (glimepiride/metformin hydrochloride&#xD;
      immediate release combination tablet) in fed conditions in healthy male and/or female&#xD;
      subjects.&#xD;
&#xD;
      Primary Objective To assess, after single oral administration under fed conditions, the&#xD;
      bioequivalence between the two batches of the same glimepiride/metformin hydrochloride (HCl)&#xD;
      2 mg/1000 mg fixed dose combination (FDC) tablets (immediate release combination tablet&#xD;
      Amaryl® M IR 2/1000) manufactured in India and in Turkey.&#xD;
&#xD;
      Secondary Objective(s) To assess the safety (including hypoglycemic events) of the two FDC&#xD;
      (Amaryl® M IR 2/1000) tablets.&#xD;
&#xD;
      Up to 50 healthy subjects are to be enrolled to have 46 subjects available for the final&#xD;
      pharmacokinetic evaluation.&#xD;
&#xD;
      Study treatment:&#xD;
&#xD;
      In each period A single dose of glimepiride/metformin HCl 2mg/1000 mg FDC (manufactured in&#xD;
      India) Or single dose of glimepiride/metformin HCl 2mg/1000 mg FDC (manufactured in Turkey)&#xD;
      will be administered after breakfast.&#xD;
&#xD;
      PRIMARY AND SECONDARY ENDPOINT(S)&#xD;
&#xD;
      Primary Endpoint:&#xD;
&#xD;
      Glimepiride and metformin: Cmax and AUClast&#xD;
&#xD;
      Secondary Endpoint(s):&#xD;
&#xD;
      Glimepiride and metformin: AUC0-inf, tlag, tmax and t1/2z Safety&#xD;
&#xD;
      DURATION OF STUDY (per patient) Screening : up to 15 days Treatments periods: 4 days each&#xD;
      including treatment day Wash-out period: 4 to 7 days Follow-up: 4 to 7 days Total study&#xD;
      duration: 37 days&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0-72</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>0-72</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>0-72</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Amaryl® M IR 2/1000 (manufactured in India)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational products :Reference formulation Trade Name: Amaryl® M IR 2/1000 (manufactured in India) Dosage Form: Film coated tablet 1x1 Active Substance: Glimepiride/metformine HCl 2 mg/1000 mg Manufacturer: Goa, India</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amaryl® M IR 2/1000 (manufactured in Turkey)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: Film coated tablet 1x1 Active substance : Glimepiride/metformine HCl 2 mg/1000 mg Manufacturer: Zentiva TR, Lüleburgaz</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>: Amaryl® M IR 2/1000</intervention_name>
    <arm_group_label>Amaryl® M IR 2/1000 (manufactured in India)</arm_group_label>
    <arm_group_label>Amaryl® M IR 2/1000 (manufactured in Turkey)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Demography&#xD;
&#xD;
          1. Male subjects and female subjects of non-childbearing potential (post- menopausal or&#xD;
             sterilized) aged 18 to 50 years inclusive.&#xD;
&#xD;
          2. Body weight between 50.0 and 95.0 kg, inclusive, if male, and between 40.0 and 85.0&#xD;
             kg, inclusive, if female, body mass index between 18.0 and 30.0 kg/m2, inclusive.&#xD;
&#xD;
               -  Health status&#xD;
&#xD;
          3. Certified as healthy by a comprehensive clinical assessment (detailed medical history&#xD;
             (hypo-, hypertension, allergy, other diseases, major surgery, micturition, defecation,&#xD;
             sleep, illness within the last 3 weeks prior start of the trial, registration of life&#xD;
             style and habits (consumption of alcohol, nicotine, coffee, tea, coke, special diet,&#xD;
             drug abuse) and complete physical examination (general state and abnormal findings per&#xD;
             system: endocrine/metabolic, allergies, drug sensitivities, head, neck, eyes, ears,&#xD;
             nose, throat, cardiovascular, respiratory, gastrointestinal, hepatic/biliary,&#xD;
             urogenital, musculoskeletal, Iymph nodes, skin, and neurological/psychiatric).&#xD;
&#xD;
          4. Normal vital signs after 10 minutes resting in supine position:&#xD;
&#xD;
               -  90 mmHg &lt; systolic blood pressure (SBP) &lt;140 mmHg&#xD;
&#xD;
               -  45 mmHg &lt; diastolic blood pressure (DBP) &lt;90 mmHg&#xD;
&#xD;
               -  40 bpm &lt; heart rate (HR) &lt;100 bpm&#xD;
&#xD;
          5. Normal standard 12-lead electrocardiogram (ECG) after 10 minutes resting in supine&#xD;
             position in the following ranges; 120 ms&lt;PR&lt;220 ms, QRS&lt;120 ms, QTc≤430 ms if male,&#xD;
             ≤450 ms if female and normal ECG tracing unless the Investigator considers an ECG&#xD;
             tracing abnormality to be not clinically relevant.&#xD;
&#xD;
          6. Laboratory parameters within the normal range (or defined screening threshold for the&#xD;
             Investigator site), unless the Investigator considers an abnormality to be clinically&#xD;
             irrelevant for healthy subjects; however blood/serum examination creatinine, alkaline&#xD;
             phosphatase, hepatic enzymes (aspartate aminotransferase, alanine aminotransferase),&#xD;
             and total bilirubin (unless the subject has documented Gilbert syndrome) should not&#xD;
             exceed the upper laboratory norm. For female of non-childbearing potential, sterilized&#xD;
             at least 3 months earlier or postmenopausal i.e. artificial or natural menopause for&#xD;
             more than 2 years with plasma FSH level &gt; 30 UI/L.&#xD;
&#xD;
        Regulations I 07. Having given written informed consent prior to undertaking any&#xD;
        study-related procedure.&#xD;
&#xD;
        I 08. Covered by a health insurance system where applicable, and/or in compliance with the&#xD;
        recommendations of the national laws in force relating to biomedical research.&#xD;
&#xD;
        I 09. Not under any administrative or legal supervision.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical history and clinical status E 01. Any history or presence of clinically&#xD;
             relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic,&#xD;
             hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular,&#xD;
             gynecologic (if female), or infectious disease, or signs of acute illness.&#xD;
&#xD;
        E 02. Frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice&#xD;
        a month).&#xD;
&#xD;
        E 03. Blood donation, any volume, within 3 months before inclusion. E 04. Symptomatic&#xD;
        hypotension, irrespective of the decrease in blood pressure. E 05. Presence or history of&#xD;
        drug hypersensitivity, or allergic disease diagnosed and treated by a physician.&#xD;
&#xD;
        E 06. Major surgery of the gastrointestinal tract except for appendectomy. E 07. History or&#xD;
        presence of drug or alcohol abuse (alcohol consumption more than 40 g per day).&#xD;
&#xD;
        E 08. Smoking more than 5 cigarettes or equivalent per day, unable to stop smoking during&#xD;
        the study.&#xD;
&#xD;
        E 09. Excessive consumption of beverages containing xanthine bases (Pepsi/cola, tea,&#xD;
        coffee) more than 4 cups or glasses per day) E 10. If female, pregnancy (defined as&#xD;
        positive β-HCG test), breast-feeding. Interfering substance E 11. Medication with drugs&#xD;
        known to alter organs or systems such as barbiturates, phenothiazines, cimetidine,&#xD;
        omeprazole etc. within the last 2 months.&#xD;
&#xD;
        E 12. Any medication (including St John's Wort) within 14 days before inclusion or within 5&#xD;
        times the elimination half-life or pharmacodynamic half-life of the medication, any&#xD;
        vaccination within the last 28 days and any biologics (antibody or its derivatives) given&#xD;
        within 4 months before inclusion.&#xD;
&#xD;
        General conditions E 13. Any subject who, in the judgment of the Investigator, is likely to&#xD;
        be noncompliant during the study, or unable to cooperate because of a language problem or&#xD;
        poor mental development.&#xD;
&#xD;
        E 14. Any subject in the exclusion period of a previous study according to applicable&#xD;
        regulations.&#xD;
&#xD;
        E 15. Any subject who cannot be contacted in case of emergency. E 16. Any subject who is&#xD;
        the Investigator or any subinvestigator, research assistant, pharmacist, study coordinator,&#xD;
        or other staff thereof, directly involved in conducting the study.&#xD;
&#xD;
        Biological status E 17. Positive result on any of the following tests: hepatitis B surface&#xD;
        (HBs Ag) antigen, anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency&#xD;
        virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab).&#xD;
&#xD;
        E 18. Positive result on urine drug screen (amphetamines/methamphetamines, barbiturates,&#xD;
        benzodiazepines, cannabinoids, cocaine, opiates).&#xD;
&#xD;
        E 19. Positive alcohol test. Specific to the study E 20. Any contra-indications to&#xD;
        glimepiride, according to the applicable labeling.&#xD;
&#xD;
        E 21. Any contra-indications to metformin, according to the applicable labeling.&#xD;
&#xD;
        E 22. Use of any CYP2C9 inhibitors and/or CYP2C9 inducers within 7 days before inclusion.&#xD;
&#xD;
        E 23. Vegetarian diet E 24. Participation in another clinical trial at same time or within&#xD;
        the preceding 3 months (calculated from the date of the final examination of the previous&#xD;
        study),except for previous BE trials in which case 80 days are sufficient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit</name>
      <address>
        <city>Amman</city>
        <zip>00962</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2015</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fed Conditions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

